Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Structural Heart Disease
Would you recommend starting an SGLT-2 inhibitors in patients with non-severe aortic stenosis based on recent evidence suggesting it may slow progression of disease?
Shah T, et al. PMID 39985508
Related Questions
How should one approach management of a patient with asymptomatic severe primary (prolapse) TR and normal RV function (EF and strain) but with RA/RV enlargement?
How do you decide the duration of DAPT following TAVR, especially for patients already on a DOAC?
Is there any role for routine CT TAVR a few months after TAVR to look for HALT?
In patients with contraindications to TEE and poor windows for TTE, what is the next best test to look for PFO?
In a patient with suspected prosthetic valve endocarditis, how long after prosthetic valve implantation is an FDG PET reasonable to rule out infection?
What is the best approach to asymptomatic severe primary tricuspid regurgitation when imaging begins to show RV enlargement?
How would you approach the INR goal in a patient with mechanical aortic valve and high bleeding risk factors like immune thrombocytopenia, AV malformations and recurrent GI bleeds, etc.?
Are there any indications for valve intervention in asymptomatic patients with moderate AS?
How would you approach anticoagulation management and consideration for PFO closure in patients with acute lower extremity DVTs involving the proximal deep veins and findings concerning for PFO on echocardiogram?
Which anticoagulant (DOAC or Warfarin) would you recommend in the case of a 70-year-old male with persistent atrial fibrillation and history of rheumatic mitral stenosis now status post bioprosthetic MVR?
